Black Diamond Therapeutics Presented Novel Real-World Evidence Of The Evolving EGFR Mutation Landscape In NSCLC And The Opportunity For BDTX-1535 In An Oral Presentation At The 2024 AACR Annual Meeting
Black Diamond Therapeutics Presented Novel Real-World Evidence Of The Evolving EGFR Mutation Landscape In NSCLC And The Opportunity For BDTX-1535 In An Oral Presentation At The 2024 AACR Annual Meeting
Black Diamond Therapeutics 在 2024 年 AACR 年会上的口头陈述中提供了新的真实世界证据，证明了 NSCLC 表皮生长因子突变格局的演变以及 BDTX-1535 的机会
- Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLC
- Emerging data show non-classical EGFR mutations can be co-expressed with the classical L858R mutation, a setting characterized by shorter duration of response to osimertinib
- BDTX-1535 profile differentiated as the most advanced fourth-generation oral TKI in clinical development addressing the full spectrum of classical, non-classical, and C797S resistance EGFR mutations
- 现实世界的数据表明，在所有 eGFrm NSCLC 患者中，有 20-30% 存在非经典突变
- 新兴数据显示，非经典表皮生长因子突变可以与经典的 L858R 突变共同表达，这种环境的特征是对奥西替尼的反应时间较短
- BDTX-1535 特征脱颖而出，成为临床开发中最先进的第四代口服 TKI，可应对全方位的经典、非经典和 C797S 耐药性 EGFR 突变